Brief: Pharming Group Nine-Month Revenues Up At $151.0 Mln

Pharming

27/10/2022 06:22

Oct 27 (Reuters) - Pharming Group NV  PHAR.AS :
    * PHARMING GROUP REPORTS EARNINGS FOR THE FIRST NINE MONTHS
OF
2022
    * LENIOLISIB REMAINS ON TRACK FOR MARKETING AUTHORIZATION IN
US
AND EUROPEAN ECONOMIC AREA IN H1 2023
    * 9M REVENUES INCREASED BY 3% TO US$151.0 MILLION, COMPARED
TO
FIRST NINE MONTHS OF 2021
    * 9M OPERATING PROFIT INCREASED BY 86% TO US$28.4 MILLION
    * REVENUES FOR FIRST NINE MONTHS OF 2022 WERE US$151.0
MILLION, A
3% INCREASE COMPARED TO FIRST NINE MONTHS OF 2021 (US$146.1
MILLION)
    * GROSS PROFIT FOR FIRST NINE MONTHS OF 2022 INCREASED 7% TO
US$139.7 MILLION
    * OPERATING PROFIT FOR FIRST NINE MONTHS OF 2022 WAS US$28.4
MILLION, INCREASING 86% VERSUS SAME PERIOD LAST YEAR
    * NET PROFIT FOR FIRST NINE MONTHS OF 2022 WAS US$28.3
MILLION, A
104% INCREASE COMPARED TO SAME PERIOD LAST YEAR (US$13.9
MILLION)
    * CASH AND CASH EQUIVALENTS, TOGETHER WITH RESTRICTED CASH,
DECREASED FROM US$193.0 MILLION AT END OF 2021, TO US$189.9
MILLION AT END OF Q3 2022
    * WE ANTICIPATE MARKETING AUTHORIZATION IN US FOR LENIOLISIB
AT
END OF Q1 2023, WITH AN ANTICIPATED LAUNCH AND COMMERCIALIZATION
IN Q2 2023
    * WE ANTICIPATE A POSITIVE OPINION FROM CHMP FOR LENIOLISIB,
FOLLOWED BY ISSUANCE OF AN MAA BY EUROPEAN COMMISSION TOWARDS
END OF H1 2023
    * WE INTEND TO SUBMIT AN ECDRP FILING FOR LENIOLISIB WITH
MHRA IN
UK IN H2 2023

Source text for Eikon:  ID:nPre4Syqda 
Further company coverage:  PHAR.AS 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))